跳至主要内容
临床试验/LBCTR2020033434
LBCTR2020033434已完成3 期

AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS - Ensemble

F. HOFFMANN-LA ROCHE LTD0 个研究点目标入组 6 人开始时间: 2024年5月17日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 至 99(—)
性别
All

入选标准

  • Participant has histologically confirmed locally advanced/metastatic (stage IIIB/IIIC or IV)
  • - Participant has a KRAS G12C mutation present in tumor tissue prior to enrollment, as determined by a Novartis designated central laboratory.
  • - Participants has received one prior platinum-based chemotherapy regimen and one prior immune checkpoint inhibitor therapy for locally advanced or metastatic disease
  • - Participant has at least 1 evaluable (measurable or non-measurable) lesion by RECIST 1.1 at the screening visit.

排除标准

  • - Participant has previously received docetaxel, KRAS G12C inhibitor or any other systemic therapy for their locally advanced or metastatic NSCLC other than one platinum-based chemotherapy and one prior immune check point inhibitor
  • - Participant has EGFR-sensitizing mutation and/or ALK rearrangement by local laboratory testing
  • - Participant has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • - Participant has an history of interstitial lung disease or pneumonitis grade > 1.

研究者

相似试验